Gilead Sciences, Inc.(NASDAQ:GILD)’s Shares Jump On Robust Earnings and Strong Guidance Print
By William Kent   
Friday, 01 May 2015 18:38

Undisputed leader in hepatitis C drugs market, Gilead Sciences, Inc. (NASDAQ:GILD), has come out with first-quarter financial results for the year. The firm has confirmed huge profits that have doubled because of amazing growth of the firm’s hepatitis C drugs franchise.

For quarter one of the financial year 2015, Gilead has confirmed large surge in profits of $4.33 billion that has grown by 94.17% year-over-year compared to profits of 1QFY14 of $2.23 billion. The firm’s adjusted earnings per share for recent quarter after exclusion of one-time costs such as restructuring or stock-based expenses from net profit was at $2.94 per share.

The adjusted EPS was a big rise of about 98.6% YoY vis-a-vis adjusted EPS figure for quarter one of previous year being at $1.43 per share. The revenues for quarter one of the year was $7.59 billion, a surge of about 52% YoY and bettering the Street’s expectations of $6.92 billion. On the other hand, revenues for latest quarter was higher by 3.08% vis-a-vis revenues of $7.31 billion for 4QFY14.

The hepatitis C drugs franchise comprises of two major blockbuster treatments: Sovaldi and Harvoni. Sovaldi is priced at $84,000 for 12-week treatment course and was initially approved in US by the Food and Drug Administration (FDA) two years back.

Gilead’s Harvoni carries a higher price tag of $94,500 for 12-week treatment and was agreed by FDA in October last year.

Combined sales of Solvaldi and Harvoni was huge $4.55 billion that’s a big contribution of 61.4% to overall revenues from firm’s product sales of $7.41 billion. Two HCV drugs are top selling products for the firm having about $12.4 billion in sales for the firm previous year.

Harvoni’s sales for quarter one was a huge $3.58 billion demonstrating surge of 67.7% vis-a-vis sales of $2.11 billion for previous year.

Shares of the company rose 5% to $105.54.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!